{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:59:30Z","timestamp":1790351970929,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA016058"],"award-info":[{"award-number":["P30CA016058"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pancreatic cancer is an aggressive disease with a 5\u00a0year survival rate of 13%. This poor survival is attributed, in part, to limited and ineffective treatments for patients with metastatic disease, highlighting a need to identify molecular drivers of pancreatic cancer to target for more effective treatment. CD200 is a glycoprotein that interacts with the receptor CD200R and elicits an immunosuppressive response. Overexpression of CD200 has been associated with differential outcomes, depending on the tumor type. In the context of pancreatic cancer, we have previously reported that CD200 is expressed in the pancreatic tumor microenvironment (TME), and that targeting CD200 in murine tumor models reduces tumor burden. We hypothesized that CD200 is overexpressed on tumor and stromal populations in the pancreatic TME and that circulating levels of soluble CD200 (sCD200) have prognostic value for overall survival. We discovered that CD200 was overexpressed on immune, stromal, and tumor populations in the pancreatic TME. Particularly, single-cell RNA-sequencing indicated that CD200 was upregulated on inflammatory cancer-associated fibroblasts. Cytometry by time of flight analysis of PBMCs indicated that CD200 was overexpressed on innate immune populations, including monocytes, dendritic cells, and monocytic myeloid-derived suppressor cells. High sCD200 levels in plasma correlated with significantly worse overall and progression-free survival. Additionally, sCD200 correlated with the ratio of circulating matrix metalloproteinase (MMP) 3: tissue inhibitor of metalloproteinase (TIMP) 3 and MMP11\/TIMP3. This study highlights the importance of CD200 expression in pancreatic cancer and provides the rationale for designing novel therapeutic strategies that target this protein.<\/jats:p>","DOI":"10.1007\/s00262-024-03678-6","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T05:01:55Z","timestamp":1713157315000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["CD200 is overexpressed in the pancreatic tumor microenvironment and predictive of overall survival"],"prefix":"10.1007","volume":"73","author":[{"given":"Jessica","family":"Wedig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrina","family":"Jasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasmita","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Lathrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Matreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Pfau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"D\u2019Alesio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Guenther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lexie","family":"Fenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly A.","family":"Torok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"McGue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina M.","family":"Sizemore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Noonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Dillhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley W.","family":"Blaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy L.","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Culp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil A.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zobeida","family":"Cruz-Monserrate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Mace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"issue":"1","key":"3678_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics. CA Cancer J Clin 74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"issue":"10039","key":"3678_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","volume":"388","author":"T Kamisawa","year":"2016","unstructured":"Kamisawa T, Wood LD, Itoi T, Takaori K (2016) Pancreatic cancer. Lancet 388(10039):73\u201385. https:\/\/doi.org\/10.1016\/S0140-6736(16)00141-0","journal-title":"Lancet"},{"issue":"28","key":"3678_CR3","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.3748\/wjg.v26.i28.4036","volume":"26","author":"GB Mpilla","year":"2020","unstructured":"Mpilla GB, Philip PA, El-Rayes B, Azmi AS (2020) Pancreatic neuroendocrine tumors: therapeutic challenges and research limitations. World J Gastroenterol 26(28):4036\u20134054. https:\/\/doi.org\/10.3748\/wjg.v26.i28.4036","journal-title":"World J Gastroenterol"},{"issue":"4","key":"3678_CR4","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jcmgh.2021.11.010","volume":"13","author":"E Backx","year":"2022","unstructured":"Backx E, Coolens K, Van den Bossche JL, Houbracken I, Espinet E, Rooman I (2022) On the origin of pancreatic cancer: molecular tumor subtypes in perspective of exocrine cell plasticity. Cell Mol Gastroenterol Hepatol 13(4):1243\u20131253. https:\/\/doi.org\/10.1016\/j.jcmgh.2021.11.010","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"3678_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070991","author":"L Moletta","year":"2019","unstructured":"Moletta L, Serafini S, Valmasoni M, Pierobon ES, Ponzoni A, Sperti C (2019) Surgery for recurrent pancreatic cancer: is it effective? Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11070991","journal-title":"Cancers (Basel)"},{"issue":"2","key":"3678_CR6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","volume":"163","author":"LD Wood","year":"2022","unstructured":"Wood LD, Canto MI, Jaffee EM, Simeone DM (2022) Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology 163(2):386-402 e1. https:\/\/doi.org\/10.1053\/j.gastro.2022.03.056","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"3678_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4137\/BiC.s34414","volume":"8","author":"F Karandish","year":"2016","unstructured":"Karandish F, Mallik S (2016) Biomarkers and targeted therapy in pancreatic cancer. Biomark Cancer 8(Suppl 1):27\u201335. https:\/\/doi.org\/10.4137\/BiC.s34414","journal-title":"Biomark Cancer"},{"key":"3678_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jbior.2017.11.007","volume":"68","author":"A Adamska","year":"2018","unstructured":"Adamska A, Elaskalani O, Emmanouilidi A, Kim M, Abdol Razak NB, Metharom P, Falasca M (2018) Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. Adv Biol Regul 68:77\u201387. https:\/\/doi.org\/10.1016\/j.jbior.2017.11.007","journal-title":"Adv Biol Regul"},{"issue":"19","key":"3678_CR9","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, Groupe Tumeurs Digestives of U, Intergroup P (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817\u20131825. https:\/\/doi.org\/10.1056\/NEJMoa1011923","journal-title":"N Engl J Med"},{"issue":"18","key":"3678_CR10","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1304369","journal-title":"N Engl J Med"},{"key":"3678_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9110157","author":"M Amrutkar","year":"2017","unstructured":"Amrutkar M, Gladhaug IP (2017) Pancreatic cancer chemoresistance to gemcitabine. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers9110157","journal-title":"Cancers (Basel)"},{"issue":"9","key":"3678_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Jaffee EM, Zheng L (2020) The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol 17(9):527\u2013540. https:\/\/doi.org\/10.1038\/s41571-020-0363-5","journal-title":"Nat Rev Clin Oncol"},{"key":"3678_CR13","doi-asserted-by":"publisher","first-page":"655152","DOI":"10.3389\/fcell.2021.655152","volume":"9","author":"X Geng","year":"2021","unstructured":"Geng X, Chen H, Zhao L, Hu J, Yang W, Li G, Cheng C, Zhao Z, Zhang T, Li L, Sun B (2021) Cancer-associated fibroblast (CAF) heterogeneity and targeting therapy of CAFs in pancreatic cancer. Front Cell Dev Biol 9:655152. https:\/\/doi.org\/10.3389\/fcell.2021.655152","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"3678_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D Ohlund","year":"2017","unstructured":"Ohlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, Chio II, Hwang CI, Tiriac H, Baker LA, Engle DD, Feig C, Kultti A, Egeblad M, Fearon DT, Crawford JM, Clevers H, Park Y, Tuveson DA (2017) Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med 214(3):579\u2013596. https:\/\/doi.org\/10.1084\/jem.20162024","journal-title":"J Exp Med"},{"issue":"10","key":"3678_CR15","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1158\/0008-5472.CAN-12-4601","volume":"73","author":"TA Mace","year":"2013","unstructured":"Mace TA, Ameen Z, Collins A, Wojcik S, Mair M, Young GS, Fuchs JR, Eubank TD, Frankel WL, Bekaii-Saab T, Bloomston M, Lesinski GB (2013) Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res 73(10):3007\u20133018. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-4601","journal-title":"Cancer Res"},{"key":"3678_CR16","doi-asserted-by":"publisher","first-page":"104254","DOI":"10.1016\/j.cellimm.2020.104254","volume":"359","author":"R Weber","year":"2021","unstructured":"Weber R, Groth C, Lasser S, Arkhypov I, Petrova V, Altevogt P, Utikal J, Umansky V (2021) IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. Cell Immunol 359:104254. https:\/\/doi.org\/10.1016\/j.cellimm.2020.104254","journal-title":"Cell Immunol"},{"issue":"7","key":"3678_CR17","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.4049\/jimmunol.1201449","volume":"190","author":"J Yu","year":"2013","unstructured":"Yu J, Du W, Yan F, Wang Y, Li H, Cao S, Yu W, Shen C, Liu J, Ren X (2013) Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 190(7):3783\u20133797. https:\/\/doi.org\/10.4049\/jimmunol.1201449","journal-title":"J Immunol"},{"issue":"1","key":"3678_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40425-019-0504-5","volume":"7","author":"JJ Miret","year":"2019","unstructured":"Miret JJ, Kirschmeier P, Koyama S, Zhu M, Li YY, Naito Y, Wu M, Malladi VS, Huang W, Walker W, Palakurthi S, Dranoff G, Hammerman PS, Pecot CV, Wong KK, Akbay EA (2019) Suppression of myeloid cell arginase activity leads to therapeutic response in a NSCLC mouse model by activating anti-tumor immunity. J Immunother Cancer 7(1):32. https:\/\/doi.org\/10.1186\/s40425-019-0504-5","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3678_CR19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1186\/s12885-019-5803-1","volume":"19","author":"M Amrutkar","year":"2019","unstructured":"Amrutkar M, Aasrum M, Verbeke CS, Gladhaug IP (2019) Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells. BMC Cancer 19(1):596. https:\/\/doi.org\/10.1186\/s12885-019-5803-1","journal-title":"BMC Cancer"},{"key":"3678_CR20","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.58688","author":"A Nicolas-Boluda","year":"2021","unstructured":"Nicolas-Boluda A, Vaquero J, Vimeux L, Guilbert T, Barrin S, Kantari-Mimoun C, Ponzo M, Renault G, Deptula P, Pogoda K, Bucki R, Cascone I, Courty J, Fouassier L, Gazeau F, Donnadieu E (2021) Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. Elife. https:\/\/doi.org\/10.7554\/eLife.58688","journal-title":"Elife"},{"issue":"1","key":"3678_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40425-019-0556-6","volume":"7","author":"DE Kuczek","year":"2019","unstructured":"Kuczek DE, Larsen AMH, Thorseth ML, Carretta M, Kalvisa A, Siersbaek MS, Simoes AMC, Roslind A, Engelholm LH, Noessner E, Donia M, Svane IM, Straten PT, Grontved L, Madsen DH (2019) Collagen density regulates the activity of tumor-infiltrating T cells. J Immunother Cancer 7(1):68. https:\/\/doi.org\/10.1186\/s40425-019-0556-6","journal-title":"J Immunother Cancer"},{"key":"3678_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-3-030-35582-1_8","volume":"1223","author":"JQ Liu","year":"2020","unstructured":"Liu JQ, Hu A, Zhu J, Yu J, Talebian F, Bai XF (2020) CD200-CD200R Pathway in the regulation of tumor immune microenvironment and immunotherapy. Adv Exp Med Biol 1223:155\u2013165. https:\/\/doi.org\/10.1007\/978-3-030-35582-1_8","journal-title":"Adv Exp Med Biol"},{"issue":"679","key":"3678_CR23","doi-asserted-by":"publisher","first-page":"eabn5029","DOI":"10.1126\/scitranslmed.abn5029","volume":"15","author":"X Wang","year":"2023","unstructured":"Wang X, Zha H, Wu W, Yuan T, Xie S, Jin Z, Long H, Yang F, Wang Z, Zhang A, Gao J, Jiang Y, Wang L, Hu C, Wan YY, Li QJ, Symonds ALJ, Jia Q, Zhu B (2023) CD200(+) cytotoxic T lymphocytes in the tumor microenvironment are crucial for efficacious anti-PD-1\/PD-L1 therapy. Sci Transl Med 15(679):eabn5029. https:\/\/doi.org\/10.1126\/scitranslmed.abn5029","journal-title":"Sci Transl Med"},{"issue":"38","key":"3678_CR24","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1038\/s41388-022-02425-4","volume":"41","author":"B Diskin","year":"2022","unstructured":"Diskin B, Adam S, Soto GS, Liria M, Aykut B, Sundberg B, Li E, Leinwand J, Chen R, Kim M, Salas RD, Cassini MF, Buttar C, Wang W, Farooq MS, Shadaloey SAA, Werba G, Fnu A, Yang F, Hirsch C, Glinski J, Panjwani A, Weitzner Y, Cohen D, Asghar U, Miller G (2022) BTLA(+)CD200(+) B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer. Oncogene 41(38):4349\u20134360. https:\/\/doi.org\/10.1038\/s41388-022-02425-4","journal-title":"Oncogene"},{"issue":"1","key":"3678_CR25","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.1038\/s41467-021-25307-x","volume":"12","author":"G Izumi","year":"2021","unstructured":"Izumi G, Nakano H, Nakano K, Whitehead GS, Grimm SA, Fessler MB, Karmaus PW, Cook DN (2021) CD11b(+) lung dendritic cells at different stages of maturation induce Th17 or Th2 differentiation. Nat Commun 12(1):5029. https:\/\/doi.org\/10.1038\/s41467-021-25307-x","journal-title":"Nat Commun"},{"issue":"4","key":"3678_CR26","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/jcmm.12752","volume":"20","author":"C Pontikoglou","year":"2016","unstructured":"Pontikoglou C, Langonne A, Ba MA, Varin A, Rosset P, Charbord P, Sensebe L, Deschaseaux F (2016) CD200 expression in human cultured bone marrow mesenchymal stem cells is induced by pro-osteogenic and pro-inflammatory cues. J Cell Mol Med 20(4):655\u2013665. https:\/\/doi.org\/10.1111\/jcmm.12752","journal-title":"J Cell Mol Med"},{"issue":"12","key":"3678_CR27","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1172\/JCI32163","volume":"117","author":"KB Petermann","year":"2007","unstructured":"Petermann KB, Rozenberg GI, Zedek D, Groben P, McKinnon K, Buehler C, Kim WY, Shields JM, Penland S, Bear JE, Thomas NE, Serody JS, Sharpless NE (2007) CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest 117(12):3922\u20133929. https:\/\/doi.org\/10.1172\/JCI32163","journal-title":"J Clin Invest"},{"issue":"12","key":"3678_CR28","doi-asserted-by":"publisher","first-page":"7744","DOI":"10.4049\/jimmunol.172.12.7744","volume":"172","author":"R Gorczynski","year":"2004","unstructured":"Gorczynski R, Chen Z, Kai Y, Lee L, Wong S, Marsden PA (2004) CD200 is a ligand for all members of the CD200R family of immunoregulatory molecules. J Immunol 172(12):7744\u20137749. https:\/\/doi.org\/10.4049\/jimmunol.172.12.7744. (PubMed PMID: 15187158)","journal-title":"J Immunol"},{"issue":"1","key":"3678_CR29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40425-014-0046-9","volume":"2","author":"CL Moertel","year":"2014","unstructured":"Moertel CL, Xia J, LaRue R, Waldron NN, Andersen BM, Prins RM, Okada H, Donson AM, Foreman NK, Hunt MA, Pennell CA, Olin MR (2014) CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy. J Immunother Cancer 2(1):46. https:\/\/doi.org\/10.1186\/s40425-014-0046-9","journal-title":"J Immunother Cancer"},{"issue":"2","key":"3678_CR30","doi-asserted-by":"publisher","first-page":"e0171586","DOI":"10.1371\/journal.pone.0171586","volume":"12","author":"A Curry","year":"2017","unstructured":"Curry A, Khatri I, Kos O, Zhu F, Gorczynski R (2017) Importance of CD200 expression by tumor or host cells to regulation of immunotherapy in a mouse breast cancer model. PLoS ONE 12(2):e0171586. https:\/\/doi.org\/10.1371\/journal.pone.0171586","journal-title":"PLoS ONE"},{"issue":"4","key":"3678_CR31","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.4049\/jimmunol.1600052","volume":"197","author":"JQ Liu","year":"2016","unstructured":"Liu JQ, Talebian F, Wu L, Liu Z, Li MS, Wu L, Zhu J, Markowitz J, Carson WE 3rd, Basu S, Bai XF (2016) A critical role for CD200R signaling in limiting the growth and metastasis of CD200+ melanoma. J Immunol 197(4):1489\u20131497. https:\/\/doi.org\/10.4049\/jimmunol.1600052","journal-title":"J Immunol"},{"issue":"2","key":"3678_CR32","doi-asserted-by":"publisher","first-page":"e31442","DOI":"10.1371\/journal.pone.0031442","volume":"7","author":"F Talebian","year":"2012","unstructured":"Talebian F, Liu JQ, Liu Z, Khattabi M, He Y, Ganju R, Bai XF (2012) Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions. PLoS ONE 7(2):e31442. https:\/\/doi.org\/10.1371\/journal.pone.0031442","journal-title":"PLoS ONE"},{"key":"3678_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000189","author":"F Choueiry","year":"2020","unstructured":"Choueiry F, Torok M, Shakya R, Agrawal K, Deems A, Benner B, Hinton A, Shaffer J, Blaser BW, Noonan AM, Williams TM, Dillhoff M, Conwell DL, Hart PA, Cruz-Monserrate Z, Bai XF, Carson WE 3rd, Mace TA (2020) CD200 promotes immunosuppression in the pancreatic tumor microenvironment. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2019-000189","journal-title":"J Immunother Cancer"},{"key":"3678_CR34","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150750","author":"HJ Morgan","year":"2022","unstructured":"Morgan HJ, Rees E, Lanfredini S, Powell KA, Gore J, Gibbs A, Lovatt C, Davies GE, Olivero C, Shorning BY, Tornillo G, Tonks A, Darley R, Wang EC, Patel GK (2022) CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI150750","journal-title":"J Clin Invest"},{"issue":"7","key":"3678_CR35","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.leukres.2013.04.014","volume":"37","author":"T Twito","year":"2013","unstructured":"Twito T, Chen Z, Khatri I, Wong K, Spaner D, Gorczynski R (2013) Ectodomain shedding of CD200 from the B-CLL cell surface is regulated by ADAM28 expression. Leuk Res 37(7):816\u2013821. https:\/\/doi.org\/10.1016\/j.leukres.2013.04.014","journal-title":"Leuk Res"},{"issue":"19","key":"3678_CR36","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1158\/0008-5472.CAN-12-1390","volume":"72","author":"KK Wong","year":"2012","unstructured":"Wong KK, Brenneman F, Chesney A, Spaner DE, Gorczynski RM (2012) Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice. Cancer Res 72(19):4931\u20134943. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1390","journal-title":"Cancer Res"},{"issue":"4","key":"3678_CR37","doi-asserted-by":"publisher","first-page":"e0152073","DOI":"10.1371\/journal.pone.0152073","volume":"11","author":"KK Wong","year":"2016","unstructured":"Wong KK, Zhu F, Khatri I, Huo Q, Spaner DE, Gorczynski RM (2016) Characterization of CD200 ectodomain shedding. PLoS ONE 11(4):e0152073. https:\/\/doi.org\/10.1371\/journal.pone.0152073","journal-title":"PLoS ONE"},{"key":"3678_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164239","author":"G D'Arena","year":"2021","unstructured":"D\u2019Arena G, Vitale C, Coscia M, Lamorte D, Pietrantuono G, Perutelli F, D\u2019Auria F, Statuto T, Valvano L, Tomasso A, Griggio V, Jones R, Mansueto G, Villani O, D\u2019Agostino S, Viglioglia V, De Feo V, Calapai F, Mannucci C, Sgambato A, Efremov DG, Laurenti L (2021) CD200 Baseline serum levels predict prognosis of chronic lymphocytic leukemia. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13164239","journal-title":"Cancers (Basel)"},{"key":"3678_CR39","doi-asserted-by":"publisher","DOI":"10.3791\/59915","author":"J Lazarus","year":"2019","unstructured":"Lazarus J, Akiska Y, Perusina Lanfranca M, Delrosario L, Sun L, Long D, Shi J, Crawford H, Di Magliano MP, Zou W, Frankel T (2019) Optimization, design and avoiding pitfalls in manual multiplex fluorescent immunohistochemistry. J Vis Exp. https:\/\/doi.org\/10.3791\/59915","journal-title":"J Vis Exp"},{"issue":"8","key":"3678_CR40","doi-asserted-by":"publisher","first-page":"107408","DOI":"10.1016\/j.isci.2023.107408","volume":"26","author":"D Mukherjee","year":"2023","unstructured":"Mukherjee D, Chakraborty S, Bercz L, D\u2019Alesio L, Wedig J, Torok MA, Pfau T, Lathrop H, Jasani S, Guenther A, McGue J, Adu-Ampratwum D, Fuchs JR, Frankel TL, Pietrzak M, Culp S, Strohecker AM, Skardal A, Mace TA (2023) Tomatidine targets ATF4-dependent signaling and induces ferroptosis to limit pancreatic cancer progression. iScience 26(8):107408. https:\/\/doi.org\/10.1016\/j.isci.2023.107408","journal-title":"iScience"},{"issue":"8","key":"3678_CR41","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, Teinor JA, Belleau P, Biffi G, Lucito MS, Sivajothi S, Armstrong TD, Engle DD, Yu KH, Hao Y, Wolfgang CL, Park Y, Preall J, Jaffee EM, Califano A, Robson P, Tuveson DA (2019) Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov 9(8):1102\u20131123. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0094","journal-title":"Cancer Discov"},{"issue":"6","key":"3678_CR42","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/mt.2016.66","volume":"24","author":"AM Noonan","year":"2016","unstructured":"Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, Mikhail S, Ciombor KK, Pant S, Aparo S, Sexton J, Marshall JL, Mace TA, Wu CS, El-Rayes B, Timmers CD, Zwiebel J, Lesinski GB, Villalona-Calero MA, Bekaii-Saab TS (2016) Randomized phase 2 trial of the oncolytic virus pelareorep (reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma. Mol Ther 24(6):1150\u20131158. https:\/\/doi.org\/10.1038\/mt.2016.66","journal-title":"Mol Ther"},{"key":"3678_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23137066","author":"J Thomas","year":"2022","unstructured":"Thomas J, Torok MA, Agrawal K, Pfau T, Vu TT, Lyberger J, Chang H, Castillo AMM, Chen M, Remaily B, Kim K, Xie Z, Dillhoff ME, Kulp SK, Behbehani GK, Cruz-Monserrate Z, Ganesan LP, Owen DH, Phelps MA, Coss CC, Mace TA (2022) The neonatal Fc receptor is elevated in monocyte-derived immune cells in pancreatic cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23137066","journal-title":"Int J Mol Sci"},{"key":"3678_CR44","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919864247","author":"CW Su","year":"2019","unstructured":"Su CW, Lin CW, Yang WE, Yang SF (2019) TIMP-3 as a therapeutic target for cancer. Ther Adv Med Oncol. https:\/\/doi.org\/10.1177\/1758835919864247","journal-title":"Ther Adv Med Oncol"},{"key":"3678_CR45","doi-asserted-by":"publisher","first-page":"105818","DOI":"10.1016\/j.intimp.2019.105818","volume":"75","author":"K Jiang","year":"2019","unstructured":"Jiang K, Li J, Zhang J, Wang L, Zhang Q, Ge J, Guo Y, Wang B, Huang Y, Yang T, Hao D, Shan L (2019) SDF-1\/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy. Int Immunopharmacol 75:105818. https:\/\/doi.org\/10.1016\/j.intimp.2019.105818","journal-title":"Int Immunopharmacol"},{"key":"3678_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123723","author":"P Mittal","year":"2020","unstructured":"Mittal P, Wang L, Akimova T, Leach CA, Clemente JC, Sender MR, Chen Y, Turunen BJ, Hancock WW (2020) The CCR2\/MCP-1 chemokine pathway and lung adenocarcinoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12123723","journal-title":"Cancers (Basel)"},{"issue":"6","key":"3678_CR47","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.4049\/jimmunol.173.6.3748","volume":"173","author":"F Fallarino","year":"2004","unstructured":"Fallarino F, Asselin-Paturel C, Vacca C, Bianchi R, Gizzi S, Fioretti MC, Trinchieri G, Grohmann U, Puccetti P (2004) Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J Immunol 173(6):3748\u20133754. https:\/\/doi.org\/10.4049\/jimmunol.173.6.3748. (PubMed PMID: 15356121)","journal-title":"J Immunol"},{"issue":"5","key":"3678_CR48","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/jnc.13492","volume":"136","author":"K Hayakawa","year":"2016","unstructured":"Hayakawa K, Wang X, Lo EH (2016) CD200 increases alternatively activated macrophages through cAMP-response element binding protein - C\/EBP-beta signaling. J Neurochem 136(5):900\u2013906. https:\/\/doi.org\/10.1111\/jnc.13492","journal-title":"J Neurochem"},{"issue":"3","key":"3678_CR49","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1136\/jcp.2003.013011","volume":"57","author":"J Li","year":"2004","unstructured":"Li J, Kleeff J, Guweidhi A, Esposito I, Berberat PO, Giese T, Buchler MW, Friess H (2004) RUNX3 expression in primary and metastatic pancreatic cancer. J Clin Pathol 57(3):294\u2013299. https:\/\/doi.org\/10.1136\/jcp.2003.013011","journal-title":"J Clin Pathol"},{"issue":"11","key":"3678_CR50","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/ijc.32733","volume":"146","author":"L Wang","year":"2020","unstructured":"Wang L, Tang W, Yang S, He P, Wang J, Gaedcke J, Strobel P, Azizian A, Ried T, Gaida MM, Yfantis HG, Lee DH, Lal A, Van den Eynde BJ, Alexander HR, Ghadimi BM, Hanna N, Hussain SP (2020) NO(*) \/RUNX3\/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer. Int J Cancer 146(11):3160\u20133169. https:\/\/doi.org\/10.1002\/ijc.32733","journal-title":"Int J Cancer"},{"issue":"19","key":"3678_CR51","doi-asserted-by":"publisher","first-page":"6684","DOI":"10.1093\/nar\/gkq554","volume":"38","author":"Z Chen","year":"2010","unstructured":"Chen Z, Ma X, Zhang J, Hu J, Gorczynski RM (2010) Alternative splicing of CD200 is regulated by an exonic splicing enhancer and SF2\/ASF. Nucleic Acids Res 38(19):6684\u20136696. https:\/\/doi.org\/10.1093\/nar\/gkq554","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"3678_CR52","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1097\/TP.0b013e318186fec2","volume":"86","author":"Z Chen","year":"2008","unstructured":"Chen Z, Chen DX, Kai Y, Khatri I, Lamptey B, Gorczynski RM (2008) Identification of an expressed truncated form of CD200, CD200tr, which is a physiologic antagonist of CD200-induced suppression. Transplantation 86(8):1116\u20131124. https:\/\/doi.org\/10.1097\/TP.0b013e318186fec2. (PubMed PMID: 18946351)","journal-title":"Transplantation"},{"issue":"1","key":"3678_CR53","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s40425-019-0734-6","volume":"7","author":"R Trovato","year":"2019","unstructured":"Trovato R, Fiore A, Sartori S, Cane S, Giugno R, Cascione L, Paiella S, Salvia R, De Sanctis F, Poffe O, Anselmi C, Hofer F, Sartoris S, Piro G, Carbone C, Corbo V, Lawlor R, Solito S, Pinton L, Mandruzzato S, Bassi C, Scarpa A, Bronte V, Ugel S (2019) Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. J Immunother Cancer 7(1):255. https:\/\/doi.org\/10.1186\/s40425-019-0734-6","journal-title":"J Immunother Cancer"},{"key":"3678_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020363","author":"FJ Hansen","year":"2023","unstructured":"Hansen FJ, David P, Akram M, Knoedler S, Mittelstadt A, Merkel S, Podolska MJ, Swierzy I, Rossdeutsch L, Klosch B, Kouhestani D, Anthuber A, Benard A, Brunner M, Krautz C, Grutzmann R, Weber GF (2023) Circulating monocytes serve as novel prognostic biomarker in pancreatic ductal adenocarcinoma patients. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15020363","journal-title":"Cancers (Basel)."},{"issue":"19","key":"3678_CR55","doi-asserted-by":"publisher","first-page":"9518","DOI":"10.1158\/0008-5472.CAN-07-0175","volume":"67","author":"CE Clark","year":"2007","unstructured":"Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH (2007) Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 67(19):9518\u20139527. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-0175. (PubMed PMID: 17909062)","journal-title":"Cancer Res"},{"issue":"2","key":"3678_CR56","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3892\/br.2016.709","volume":"5","author":"B Celik","year":"2016","unstructured":"Celik B, Yalcin AD, Genc GE, Bulut T, Kuloglu Genc S, Gumuslu S (2016) CXCL8, IL-1beta and sCD200 are pro-inflammatory cytokines and their levels increase in the circulation of breast carcinoma patients. Biomed Rep 5(2):259\u2013263. https:\/\/doi.org\/10.3892\/br.2016.709","journal-title":"Biomed Rep"},{"key":"3678_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249739","author":"GA Cabral-Pacheco","year":"2020","unstructured":"Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acuna JM, Perez-Romero BA, Guerrero-Rodriguez JF, Martinez-Avila N, Martinez-Fierro ML (2020) The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21249739","journal-title":"Int J Mol Sci"},{"issue":"11\u201312","key":"3678_CR58","doi-asserted-by":"publisher","first-page":"480","DOI":"10.18632\/genesandcancer.90","volume":"6","author":"C Mehner","year":"2015","unstructured":"Mehner C, Miller E, Nassar A, Bamlet WR, Radisky ES, Radisky DC (2015) Tumor cell expression of MMP3 as a prognostic factor for poor survival in pancreatic, pulmonary, and mammary carcinoma. Genes Cancer 6(11\u201312):480\u2013489. https:\/\/doi.org\/10.18632\/genesandcancer.90","journal-title":"Genes Cancer"},{"issue":"6","key":"3678_CR59","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1097\/MPA.0000000000001583","volume":"49","author":"X Zhang","year":"2020","unstructured":"Zhang X, Lu J, Zhou L, You L, Liang Z, Guo J, Zhao Y (2020) Matrix Metalloproteinase 11 as a novel tumor promoter and diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Pancreas 49(6):812\u2013821. https:\/\/doi.org\/10.1097\/MPA.0000000000001583. (PubMed PMID: 32590618)","journal-title":"Pancreas"},{"issue":"1","key":"3678_CR60","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1183\/09031936.00146510","volume":"38","author":"S Loffek","year":"2011","unstructured":"Loffek S, Schilling O, Franzke CW (2011) Series \u201cmatrix metalloproteinases in lung health and disease\u201d: Biological role of matrix metalloproteinases: a critical balance. Eur Respir J 38(1):191\u2013208. https:\/\/doi.org\/10.1183\/09031936.00146510","journal-title":"Eur Respir J"},{"issue":"7","key":"3678_CR61","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.tibs.2005.05.006","volume":"30","author":"AP Huovila","year":"2005","unstructured":"Huovila AP, Turner AJ, Pelto-Huikko M, Karkkainen I, Ortiz RM (2005) Shedding light on ADAM metalloproteinases. Trends Biochem Sci 30(7):413\u2013422. https:\/\/doi.org\/10.1016\/j.tibs.2005.05.006. (PubMed PMID: 15949939)","journal-title":"Trends Biochem Sci"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03678-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03678-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03678-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T13:02:05Z","timestamp":1715432525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03678-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":61,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["3678"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03678-6","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]},"assertion":[{"value":"19 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare that they have no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All patients provided voluntary written informed consent (Institutional Review Board protocol: 2010C0051 and 2010C0055) to participate. The protocols and subsequent amendments were approved by The Ohio State University Institutional Review Board. All other experiments were completed under the research protocols (2014R00000086; 2013R00000056) approved by The Ohio State University Institutional Biosafety Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"96"}}